Relation logo — Discovering the relationships at the heart of biology
to cur...

Relation

Discovering the relationships at the heart of biology to cure disease.

Founded 2019 United Kingdom London, United Kingdom 147 employees Total: $139.00M Biotechnology, Pharmaceutical

General Information

Company Name Relation
Founded Year 2019
Location United Kingdom London, United Kingdom
Employees 147
Industries Biotechnology, Pharmaceutical
Business Model B2B, Platform, B2B2C
Revenue Model Licensing, Product Sales, Project Based
Social

BounceWatch is an independent company data service, not affiliated with Relation. To contact Relation, visit relationrx.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Relation compare?

A PDF of Relation and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Relation soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

Recorded by Bounce Watch from public sources. Every entry below carries the date we observed it, and when we have not looked recently the page says so rather than leaving silence to imply nothing happened.

In The News Oct 07, 2026

Featured on Thenextweb: Rivercell raises $25M to build an AI model of how cells respond to drugs

About Relation

Relation is a forward-thinking biotech startup, founded in 2019, that is making waves in the Biotechnology and Pharmaceutical industries. Headquartered in the United Kingdom, the company focuses on developing transformational medicines with cutting-edge technology at its core.

Guided by its slogan, "Discovering the relationships at the heart of biology to cure disease," Relation aims to revolutionize the understanding of human biology. By harnessing single-cell and multi-omics measurements alongside machine learning, the company seeks to discover novel therapies to address some of the most devastating diseases. Its unique Lab-in-the-Loop integrates these technologies to identify drug targets and develop breakthrough medicines.

In its latest venture capital round, Relation secured a $55.00M Late VC investment from Novartis on 01 December 2025. This substantial backing underscores the strong investor confidence in Relation's innovative approach and its potential to disrupt traditional healthcare paradigms.

Business keywords: Biotech, Transformational Medicines, Single-cell Analysis, Multi-omics, Machine Learning in Biotech, Genomics, Functional Genomics, Drug Discovery, Human Genetics, Clinical Omics, Patient-derived Tissue Samples, Therapeutic Program Development, Lab-in-the-Loop, Disease Understanding, Target Validation

Services & Products

AI-enabled drug discovery
Mechanistic disease understanding
Clinical value inflection point development
Collaborations with pharmaceutical companies

Target Customers

Biotech and pharmaceutical companies Healthcare professionals Patients with bone, cardiorenal, dermatology, or rheumatology conditions Clinical researchers

Funding Rounds & Investors (5)

View All
Funding Stage Amount Investors Lead Investors Date
Late VC $55.00M 1
Novartis
01 Dec 2025
Growth Equity VC $15.00M 1
GSK
01 Dec 2024
Late VC $35.00M -
01 Mar 2024
Seed $25.00M 8
DCVC, Firstminute capital +6
01 Jun 2022
Late VC $9.00M -
01 Aug 2021

Relation Alternatives & Competitors

View All Alternatives
Relation vs
Cajal Therapeutics
Cajal Therapeutics United States

Cajal Therapeutics is a Seattle biotechnology company dedicated to developing innovative medicines f...

Series A
38 employees
Biotechnology, Health and Wellness
Relation vs
Parallel Bio
Parallel Bio United States

Using the immune system to cure disease.

Series A
27 employees
Biotechnology, Health and Wellness
Relation vs

We aspire to be a world class innovative drug discovery company from China.

35 employees
Biotechnology, Pharmaceutical

FAQ About Relation

Discovering the relationships at the heart of biology to cure disease.
Relation was founded in 2019.
Relation is headquartered in London, United Kingdom.
Relation operates in Biotechnology and Pharmaceutical. Its work centres on Biotech, Transformational Medicines, Single-cell Analysis and Multi-omics. Its customers include Biotech and pharmaceutical companies, Healthcare professionals and Patients with bone, cardiorenal, dermatology, or rheumatology conditions.
Relation has a B2B, Platform and B2B2C business model. Its revenue comes from Licensing, Product Sales and Project Based.
Relation has approximately 147 employees.
Relation has completed 5 funding rounds, raising a total of $139.00M.
Relation offers: AI-enabled drug discovery, Mechanistic disease understanding, Clinical value inflection point development, Collaborations with pharmaceutical companies.
Top alternatives and competitors to Relation include Cajal Therapeutics, Parallel Bio, Regor Therapeutics Group, Novartis, Immunai. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Relation and Cajal Therapeutics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Relation, https://bouncewatch.com/company/relation, updated 21 September 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes